Summary
EudraCT Number: 2009-014388-38
Sponsor's Protocol Code Number: NEUAZ1
National Competent Authority: UK - MHRA 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2010-08-04
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014388-38/GB/

A. Protocol Information
A.1 Member State Concerned: UK - MHRA
A.2 EudraCT number: 2009-014388-38
A.3 Full title of the trial: A double-blind, parallel group, randomized, placebo controlled study of  the efficacy of Circadin® 2mg in alleviating sleep disturbances in patients with mild to moderate Alzheimer Disease (AD) treated with Acetylcholinesterase (AChE) inhibitor.  
A.3.2 Name or abbreviated title of the trial where available: Sleep problems in patients with mild to moderate Alzheimers Disease
A.4.1 Sponsor's protocol code number: NEUAZ1
A.5.1 ISRCTN (International Standard Randomised Controlled Trial) number: N/A
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: Neurim Pharmaceuticals Ltd
B.1.3.4	Country: Israel
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Circadin 2mg
D.2.1.1.2 Name of the Marketing Authorisation holder: RAD Neurim Pharmaceuticals EEC Ltd
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Circadin
D.3.4 Pharmaceutical form: Prolonged-release tablet
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Melatonin
D.3.9.1 CAS number: 73/31/4
D.3.9.2 Current sponsor code: N/A
D.3.9.3 Other descriptive name: Circadin
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 2 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: Information not present in EudraCT
D.3.11.3.2 Gene therapy medical product: Information not present in EudraCT
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo
D.8 Placebo: 1
D.8.1 Is a Placebo used in this Trial? Yes
D.8.3 Pharmaceutical form of the placebo: Tablet
D.8.4 Route of administration of the placebo: Oral use

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Insomnia in patients with mild to moderate Alzheimers Disease.
MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Version: 10.
E.1.2 Level: LLT
E.1.2 Classification code: 10036701
E.1.2 Term: Primary Insomnia
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: To compare the effect of Circadin® to that of placebo, on sleep quality as assessed by the Daily Sleep Diary after 12 weeks of the double-blind treatment period. 

E.2.2 Secondary objectives of the trial: - To compare the effect of Circadin® to that of placebo onCognitive parameters,
  assessed by ADAS-cog, after 12 and 24 weeks of double-blind treatment.
 
- To compare the global treatment effect of Circadin® to that of placebo over the
  24-week double blind treatment period and treatment effect after 3, 12 and 24 
  weeks of double-blind treatment period on sleep variables derived from the Daily
  sleep diary and PSQI. 


- To compare the global treatment effect of Circadin® to that of placebo over the
  24-week double-blind treatment period and treatment effects after 3, 12 and 24 
  weeks of the double blind treatment period on total sleep time, as measured by
  actigraphy (ActiWatch). 

– To compare the safety and tolerability of Circadin® treatment to that of placebo.

E.2.3 Trial contains a sub-study: No
E.3 Principal inclusion criteria: 1) Suffering from sleep disturbances, characterized by poor sleep quality
rating as assessed at screening.
2) Written informed consent as dictated by local legal circumstances.
3) Age range: adult patients between 50-85 years of age.
4) Gender: men and women. Women of child bearing potential or within two years of the menopause must have a negative urine pregnancy test at the Screening Visit.
5)	A documented history of confirmed Alzheimer's disease
6)	Dementia severity: MMSE score > 18, 
7)	Stable AChE inhibitor dose for 2 months prior to Screening visit.
8)	Stable medications for non-excluded concurrent medical conditions for four weeks prior to the screening visit.
9)	Stable doses of B12 and/or Folic acid supplements for at least 3 months prior to enrollment and throughout the study.
10)	Cranial image: no evidence of focal disease to account for dementia (established by CT, PET or MRI). If there is no such available scan (CT, PET or MRI), one must be performed prior to enrollment.
11)	Health: Physically acceptable for the study with no pathology likely to occur during or immediately after the study, as confirmed by medical history and exam and ECG.
12)	Clinical laboratory values must be within normal limits, or judged not clinically significant by the investigator. 
13)	Residence: Stable home situation with no planned move during the 28-week investigational period.
14)	A family member or a regular caregiver that will be available for visits and will ensure compliance. The caregiver must speak fluent Hebrew, Russian or English.
15)	Ability to ingest oral medication and participate in all scheduled evaluations.
16)	Ability to spend 2 daily hours outdoors exposed to sunlight.

E.4 Principal exclusion criteria: 1)	Severe agitation.
2)	Unstable medical condition, mental retardation.
3)	moderate to severe depression as defined by DSM-IV 
4)	Use of benzodiazepines or other hypnotics during the study and the preceding four weeks.
5)	Use of Circadin® during the two weeks prior to study enrollment.
6)	Pharmacological immunosuppression.
7)	Participation in a clinical trial with any investigational agent within two months prior to study enrollment.
8)	Alcoholism.
9)	Known or suspected hypersensitivity to exogenous   melatonin or melatonin receptor agonists.
10)	Patients with rare hereditary problems of galacatose intolerance, the LAPP lactose deficiency or glucose mal absorption.
11)	Renal Failure with creatinine >150 mol/l.
12)	Hepatic Failure with ASAT; ALAT; GGT levels above three times the upper normal limit. 
13)	Clinically significant abnormal laboratory findings which have not been approved by the Safety Officer (sponsor)
14)	Other serious diseases that could interfere with patient assessment.
15)	Caregivers who are unwilling or unable to give informed consent or otherwise fulfill requirements of the study.
16)	Untreated B12 and/or Folic acid deficiency.

E.5 End points
E.5.1 Primary end point(s): The effect of Circadin to that of placebo, on sleep quality as assessed by the Daily Sleep Diary after 12 weeks of double-blind treatment. 
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: No
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: Information not present in EudraCT
E.7.1.2 Bioequivalence study: Information not present in EudraCT
E.7.1.3 Other: Information not present in EudraCT
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): Yes
E.7.3 Therapeutic confirmatory (Phase III): No
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: No
E.8.1.3 Single blind: Yes
E.8.1.4 Double blind: Yes
E.8.1.5 Parallel group: Yes
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): No
E.8.2.2 Placebo: Yes
E.8.2.3 Other: No
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.4.1 Number of sites anticipated in Member State concerned: 3
E.8.5 The trial involves multiple Member States: No
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: Yes
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.6.3 If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned:
E.8.7 Trial has a data monitoring committee: No
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: 
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 1
E.8.9.1 In the Member State concerned months: 3
E.8.9.1 In the Member State concerned days: 3
E.8.9.2 In all countries concerned by the trial years: 1
E.8.9.2 In all countries concerned by the trial months: 3
E.8.9.2 In all countries concerned by the trial days: 3

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: Information not present in EudraCT
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): Information not present in EudraCT
F.1.1.3 Newborns (0-27 days): Information not present in EudraCT
F.1.1.4 Infants and toddlers (28 days-23 months): Information not present in EudraCT
F.1.1.5 Children (2-11years): Information not present in EudraCT
F.1.1.6 Adolescents (12-17 years): Information not present in EudraCT
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): Yes
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Yes
F.3.3.1 Women of childbearing potential not using contraception : Yes
F.3.3.2 Women of child-bearing potential using contraception: No
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: Yes
F.3.3.6.1 Details of subjects incapable of giving consent: Patients with Mild to moderate alzheimers disease. 
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 60
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 60
F.4.2.2 In the whole clinical trial: 210
F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition): Circadin is a marketed product which the physician may decide to prescribe on conclusion of the trial. 

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2009-09-02
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2009-09-28

P. End of Trial
P. End of Trial Status: Completed
P. Date of the global end of the trial: 2012-06-11

